Multicenter Trial Estimating the Persistence of Molecular Remission in Chronic Myeloid Leukaemia in Long Term After Stopping Imatinib

Not Applicable

Completed

• Conditions: Chronic Myeloid Leukaemia
• Interventions: Drug: Imatinib stop

• Registration Number: NCT01343173
• Lead Sponsor: University Hospital, Bordeaux

Brief Summary

Background: Complete molecular remission under imatinib, therapeutic interruption possible for patients in complete remission proved in different trials.

Purpose: Stopping imatinib in patients with chronic myeloid leukemia in complete molecular remission during two following years. The objectives of this study are to determine the rate of patients without a molecular relapse and so the rate of molecular relapse, to determine and to seek for clinical and biological CML-related factors predictive for a molecular relapse after imatinib discontinuation. These objectives require to increase the number of study patients to be enrolled for accurate statistical considerations. It will allow to predict which patients have to be proposed for discontinuation without risk of molecular relapse and to select the patients who need to continue or reinforce the treatment to achieve a complete long term eradication of the disease.

Detailed Description

The gold standard for the treatment of chronic myeloid leukaemia (CML) is Imatinib, the first tyrosine inhibitor (TKI) of BCR-ABL. Imatinib specifically targets the BCR-ABL tyrosine kinase encoded by the BCR-ABL fusion gene, the molecular hallmark of CML. Regular monitoring of BCR-ABL transcript levels by quantitative RT-PCR is of key importance for the assessment of treatment response to imatinib.

Over time, an increasing proportion of imatinib-treated patients obtain a complete molecular response (CMR), defined as an undetectable molecular residual disease. In a previous study, STIM trial (PHRC 2006, stop Imatinib), 100 patients were included. The preliminary analysis among 69 patients having a median follow up of 21 months shows that the probability to maintain the CMR at 12 months is 45%. Our goal is actually to include up to 200 patients and then let the STIM opened during 3 years in a way to determine the predictive factors of the molecular relapse Discontinuation of treatment is proposed after checking selection criteria and signing informed consent. The assessment of BCR-ABL in peripheral blood by quantitative RT-PCR is performed every month during the first year then every two months second year then every three months during 3 years.

The molecular relapse after imatinib discontinuation is defined by positive PCR for BCR-ABL two times using RTQ-PCR with increasing of the transcript on two following assessment and or a value\> 0.1% i.e. lost of MMR. In case of molecular relapse it is recommended to re-challenge an imatinib treatment. According to our experience the 50 patients well documented who re challenged the treatment were sensitive again. The treatment of molecular relapse by second generation tyrosine kinase inhibitors (dasatinib or nilotinib) will possible in the current trial. It is important for all the French patients to be included in a national trial to avoid discontinuation without evaluation.

Study Timeline

• Study First Submitted: 2011-03-23
• Study Start: 2011-04-06
• Study First Submitted QC: 2011-04-26
• Study First Posted: 2011-04-27
• Primary Completion: 2017-05-30
• Study Completion: 2017-05-30
• Status Verified: 2018-03
• Last Update Submitted: 2018-03-12
• Last Update Posted: 2018-03-13

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 220

Inclusion Criteria

• 18 years and older.
• Chronic myeloid leukaemia in chronic or accelerated phase under treatment with imatinib for at least 3 years.
• Complete molecular remission under treatment with imatinib for at least 2 years.
• HIV serology negative and absence of chronic hepatitis B or C.
• Molecular monitoring according to the international recommendations before the beginning of the study
• For the women old enough to procreate, method of effective contraception
• All patients must be informed of the investigational nature of this study and must sign and give written informed consent.

Exclusion Criteria

• Under 18 years old.
• Pregnant at the inclusion's time.
• Hospitalized patients without consent.
• Adults under law protection or without ability to assent.
• Previous or planned allogeneic stem cell transplantation.
• HIV serology positive or chronic hepatitis B or C.
• Interfering treatment (corticosteroids, immunosuppressors, chemotherapy, radiotherapy).

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
Patients	Imatinib stop	-

Primary Outcome Measures

Name	Time	Method
Rate of molecular relapse defined by the rate of patients having a significant increasing of BCR-ABL transcript.	Every months during two years

Secondary Outcome Measures

Name	Time	Method
Overall survival	after two years	Number of patients alive or died will be measured
Clinical and biological profile of patient with complete molecular remission persistence	after two years	The relevant clinical and biological factors which could be predictive of the the complete molecular remission persistence will be measured by dosage in the blood.
Treatment costs according to days without imatinib.	after two years
Event-free survival	after two years	All adverse events will be reported to know what kind of adverse events occured to patients without treatment, number of patients with adverse events and in particular number of patients with lost of complete molecular remission.

Trial Locations

Locations (32)

University Hospital Angers; 🇫🇷 Angers, France

CH Annecy; 🇫🇷 Annecy, France

CHU Bensançon; 🇫🇷 Besançon, France

Institut Bergonié; 🇫🇷 Bordeaux, France

Hôpital Morvan; 🇫🇷 Brest, France

CHU Caen; 🇫🇷 Caen, France

Hôpitaux civils de Colmar; 🇫🇷 Colmar, France

CH Sud Francilien; 🇫🇷 Corbeil-Essonnes, France

Hôpital Henri-Mondor; 🇫🇷 Creteil, France

CHU Grenoble; 🇫🇷 Grenoble, France

Scroll for more (22 remaining)